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Abstract The cytokine interleukin-6 (IL-6) rapidly activates a 
latent cytoplasmic transcription factor, acute-phase response fac- 
tor (APRF), by tyrosine phosphorylation. Activation and DNA 
binding of APRF are inhibited by inhibitors of protein tyrosine 
kinases but not serinelthreonine kinases. However, immediate- 
early gene induction by IL-6 and, as we show here, stimulaton of 
the promoters of the genes for az-macroglobulin, Jun-B, and 
intercellular adhesion molecule-I (ICAM-I) are blocked by the 
serinelthreonine kinase inhibitor 1-17. We now show that IL-6 
triggers a delayed phosphorylation of APRF at serine resudues 
which can be reversed in vitro by protein phosphatase 2A and is 
also inhibited by H7. Therefore, APRF serine phosphorylation is
likely to represent a crucial event in IL-6 signal transduction 
leading to target gene induction. 
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1. Introduction 
IL-6 is a pleiotropic ytokine controlling rowth, differentia- 
tion, and other cellular functions of a variety of cell types [1]. 
As a major mediator of the acute-phase r sponse in the liver, 
IL-6 induces the expression of many acute-phase plasma pro- 
tein genes in hepatocytes [2,3]. Furthermore, the actions of IL-6 
include the rapid induction of several immediate-early esponse 
genes, e.g. jun-B, interferon regulatory factor 1 (IRF-1), inter- 
cellular adhesion molecule 1 (ICAM-1), and TIS11, in target 
cells [4-6]. 
Major components of the IL-6 signal tranduction pathway 
to the nucleus have recently been identified. IL-6 binds to a 
plasma membrane receptor composed of a ligand-binding sub- 
unit, gp80, and a signal transducer, gpl30 [7,8]. The latter 
component is also part of the receptors for the cytokines inter- 
leukin-11 (IL-11), leukemia inhibitory factor (LIF), oncostatin 
M, and ciliary neurotrophic factor (CNTF) [9-11]. Neither 
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gp80 nor gpl30 contain cytoplasmic protein tyrosine kinase 
domains, but recent data from our laboratory as well as from 
others demonstrate hat gp 130 is constitutively associated with 
members of the Jak family of protein tyrosine kinases [12,13]. 
After binding of IL-6 to gp80, three members of this family, i.e. 
Jak 1, Jak 2, and Tyk 2, are rapidly tyrosine phosphorylated 
and activated [12,13]. 
We have previously identified a ubiquitous transcription fac- 
tor, APRF, which, in response to IL-6, transiently associates 
with gpl30 and then is tyrosine phosphorylated and translo- 
cated to the nucleus [12,14]. On the basis of immunological 
cross-reactivity and DNA-binding specificities we proposed a
relationship of APRF to the interferon-),-activated ranscrip- 
tion factor Stat 1 [15]. In fact, recent cloning of murine and 
human APRF cDNA clones revealed an about 50% overall 
homology of APRF with Stat 1 [16,17]. Thus, APRF, now also 
called Stat 3, belongs to a growing family (the Stat family) of 
signal transducing and transactivating proteins which all are 
recruited by tyrosine phosphorylation from latent cytoplasmic 
forms in response to cytokines, hormones, and growth factors 
[16,18-21]. In the nucleus, APRF bnds to IL-6 response le- 
ments (IL-6REs) in the flanking regions of many acute-phase 
protein genes [14]. Furthermore, we could demonstrate itsbind- 
ing to IL-6REs in the promoters of the immediate-early genes 
IRF-1, ICAM-I, and junB [22,23]. Therefore, APRF is likely 
to represent an important regulator of IL-6 target gene expres- 
sion. 
The induction of the Jun-B and IRF-1 immediate-early genes 
by 1L-6 was shown to be blocked by H7, and inhibitor of 
various protein serine/threonine kinases [5,6]. APRF tyrosine 
phosphorylation, uclear translocation, and DNA binding, 
however, are not sensitive to H7 [15]. Therefore, an as yet 
unknown H7-sensitive vent must be involved in the induction 
of at least some IL-6 target genes. 
We now demonstrate hat, subsequent to the rapid phospho- 
rylation of APRF at tyrosine, IL-6 also induces the serine 
phosphorylation of the factor, albeit with a delayed time- 
course. This latter modification is inhibited by H7 and is re- 
versed upon incubation with protein phosphatase 2A. These 
data provide evidence that APRF activity is regulated at two 
levels: tyrosine phosphorylation triggers the translocation of 
APRF to the nucleus and its binding to DNA while serine 
phosphorylation may be involved in the regulation of other 
functions of the factor, e.g. its transactivating potential, and 
therefore represent and important step in IL-6 signal transduc- 
tion to the nucleus. 
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2. Materials and methods 
2.1. Materials 
Recombinant human IL-6 was a generous gift from Drs. T. 
Kishimoto and T. Taga, Osaka, Japan. Amounts of IL-6 used to stim- 
ulate cells are given in B-cell stimulatory factor 2 units. The protein 
kinase inhibitors H7 and genistein were purchased from Sigma nd 
Gibco-BRL, respectively. Purified protein phosphatases 1 and 2A were 
generously provided by Dr. Goris, Leuven; and expression vectors for 
the dominant negative Ras-mutant ASN-17 and the dominant-negative 
mutant of Raf kinase, NARaf, by Dr. J. Bos, Utrecht. A vector contain- 
ing 1014 bp of the 5' flanking region of the human ICAM-1 gene fused 
to the luciferase gene was a gift from Dr. Johnson, Munich, Germany. 
Construction of the vectors used for transient transfection has been 
reported previously. The following plasmids were used: p~zM-215CAT 
contains 215 bp of the rat c~2-macroglobulin promoter fused to the 
bacterial chloramphenicol acetyltransferase (CAT) gene [22]; pA- 
PREtkCAT contains the IL-6RE (APRE) of the rat ~2-macroglobulin 
promoter fused to the Herpes virus thymidine kinase (tk) promoter and 
the CAT gene [22]; plC-l014 consists of 1014 bp of the human ICAM-1 
promoter fused to the fire-fly luciferase gene [24]; 2 × plREtkluc con- 
tains two copies of the IL-6RE (plRE) of the ICAM-1 promoter in 
front of the tk promoter and the luciferase gene [24]; pJB 1 contains 848 
bp of the murine Jun-B promoter fused to CAT [23]; and pJI-tkCAT 
the IL-6RE of the Jun-B promoter fused to the tk promoter and the 
CAT gene [23]. The polyclonal ntiserum raised against the NH2-termi- 
nal 60 amino acids of Stat 1 has been described [25]. 
2.2. Transient transfections 
Cultivation and transient transfection ofhuman hepatoma HepG2 
cells were as previously described [22]. Briefly, HepG2 cells were trans- 
fected using calcium phosphate precipitates [26] containing 6gg of 
reporter plasmids and 4 ktg of the expression vector for fl-galactosidase 
pSV-LacZ [23] as an internal control for transfection efficiency, were 
stimulated without or with IL-6 one day after transfection for an addi- 
tional 4 h, and harvested thereafter. Protein extracts prepared by 
freeze-thawing [27] were assayed for fl-galactosidase [28], CAT [29], 
and luciferase activities [30] as described. Units of CAT or luciferase 
activities were normalized to fl-galactosidase activity. All transfections 
were carried out three times in independent experiments. 
2.3. Gel retardation analysis 
Nuclear proteins of HepG2 cells were extracted as previously de- 
scribed [14]. A double-stranded synthetic oligonucleotide comprising 
the IL-6RE of the ICAM-1 promoter (upper strand: 5'-AGCTTAG- 
GTTTCCGGGAAAGCAC-3') was 32p-labelled by filling in the 5'- 
protruding ends with Klenow enzyme. Gel retardation analysis using 
a native 4% polyacrylamide g lwas performed as previously described 
[141, 
2.4. Immunoprecipitations a dimmunoblot analysis 
HepG2 cells (107) were rinsed with cold phosphate-buffered saline 
(PBS) and lysed in 0.5 ml lysis buffer (50 mM Tris (pH 7.5), 150 mM 
NaCI, 1 mM EDTA, 0.5% NP-40, 1 mM sodium orthovanadate, 1 mM 
NaF, 0.75 mM phenylmethylsulfonyl fluoride, 15% glycerol, and 10 
/.tg/ml each of aprotinin, pepstatin, and leupeptin) for 20 min at 0 ° C. 
Proteins in the lysates were immunoprecipitated with anti-Stat 1-NH2 
(4/11). Immune complexes were separated by SDS-PAGE on a 7% gel, 
transferred topolyvinyldifluoride m mbrane (Qiabrane; Diagen), and 
probed with monoclonal ntibodies to phosphotyrosine (PY20; ICN). 
The bands were visualized by enhanced chemiluminescence (ECL; 
Amersham). 
3. Results 
3.1. IL-6-stimulation of the ct2-macroglobulin, Jun-B, and 
ICAM-1 promoters is inhibited by H7 
The induction of the immediate-early esponse genes jun-B, 
IRF-1, and TIS11 in B-cell hybridoma nd myeloid leukemia 
cells is blocked by both protein tyrosine kinase inhibitors and 
the serine/threonine kinase inhibitor H7 [5,6]. To determine 
whether this observation reflects a general feature of IL-6 sig- 
nalling we analyzed the effects of protein kinase inhibitors on 
the stimulation of IL-6-responsive promoters in the human 
hepatoma cell line, HepG2. We used the promoters of three 
IL-6 target genes, the czz-macroglobulin gene, a major acute- 
phase protein gene in the rat, and the murine Jun-B and human 
ICAM-1 genes. HepG2 cells were transiently transfected with 
constructs containing 215 bp of the ct2-macroglobulin promoter 
or 846 bp of the Jun-B promoter fused to the bacterial CAT 
reporter gene, or 1000 bp of the human ICAM-1 promoter 
fused to the fire-fly luciferase gene. Transfected cells preincu- 
bated either without or with H7 were then stimulated with IL-6 
for 4 h. Measurement in cell homogenates of CAT and lucif- 
erase enzyme activities howed strong inhibitory effects of H7 
on the IL-6 stimulation of all three promoters (Fig. 1A). 
3.2. H7 inhibits the transactivation from IL-6REs 
The IL-6REs of the ~2-macroglobulin, Jun-B, and ICAM-1 
promoters have all been shown to contain APRF binding sites 
and to confer IL-6 responsiveness to heterologous promoters 
[22,23]. In order to analyze whether the H7 sensitivity of target 
gene induction reflects the action of IL-6 onto these IL-6REs 
or involves other cis-acting elements present in the promoters 
we next transfected constructs containing either one or two 
copies of the three IL-6REs fused to the Herpes virus thymidine 
kinase (tk) promoter and the luciferase gene. Again, the stimu- 
latory effect of IL-6 was found to be inhibited by H7 (Fig. 1B) 
while the activity of the tk promoter alone was not affected by 
the inhibitors (data not shown). We conclude that the action 
of an H7-sensitive protein kinase is required for the induction 
of acute-phase protein and immediate-early genes in hepatoma 
cells and that this effect is mediated through the IL-6REs pres- 
ent in their promoters. 
3.3. ct2-Macroglobulin and ICAM-1 promoter stimulation by 
IL-6 does not require activation of  the Ras pathway 
In several cell lines, an activation of p21 "as and the MAP 
kinase pathway by IL-6 has been observed [31,32]. NF-IL6, a 
member of the C/EBP family of transcription factors, is likely 
to be phosphorylated byMAP kinase in response to IL-6 [33]. 
Therefore, an H7-sensitive protein kinase involved in IL-6 tar- 
get gene induction may be activated via this pathway. In fact, 
we observed a significant activation of p2 l'aS by IL-6 in HepG2 
cells as well [23]. To study whether the Ras pathway is involved 
in the early induction of 1L-6 target genes we analyzed the effect 
of dominant negative mutants of c-Ha-Ras (ASN-17) and the 
Raf-1 kinase (NARaF) on the stimulation of the ICAM-1, Jun- 
B, and ct2-macroglobulin promoters by IL-6. Expression vec- 
tors coding for ASN-17 or NARaf were co-transfected with 
ICAM- 1, Jun-B, and ~2-macroglobulin promoter constructs 
into HepG2 cells. As shown in Fig. 1C, expression of the mu- 
tant proteins did not block the IL-6 effect on these promoters 
while under the same conditions both mutants inhibited serum 
induction of the serum response lement (SRE)-containing 
CAT- reporter construct [23]. Similarly, expression of ASN-17 
showed no effect on the IL-6 stimulation ofa construct ontain- 
ing two copies of the ICAM-1 IL-6RE fused to the tk promoter 
(Fig. 1C). We conclude that the activation of p2W s and Raf-1 
kinase is not required for the induction of the ICAM-I and 
~Zz-macroglobulin genes by IL-6. 
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3.4. IL-6-induced APRF binding to the ICAM-1 IL-6RE is not 
inhibited by H7 
In contrast to gene induction, the IL-6-induced tyrosine 
phosphorylation and nuclear translocation of APRF  are not 
-215 
inhibited by H7 [15]. Furthermore, we have previously demon- 
strated that H7 pretreatment does not prevent APRF  from 
binding to the c~2-macroglobulin a d Jun-B IL-6REs [15,23]. As 
shown in Fig. 2, the same holds true for binding of APRF  to 
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Fig. 1. Activation of IL-6 target gene promoters i inhibited by H7. HepG2 cells were transfected by the calcium-phosphate co-precipitation method 
with 6/.tg of the indicated constructs and 4/lg of the fl-galactosidase expression vector pSV-LacZ (A, B), or with 6/.tg of the receptor constructs, 
2/tg pSV-LacZ, and 4/lg of either NARaf, Ras(ASN-17), or pUC 18 (C). One day after transfection, the cells were stimulated with human recombinant 
IL-6 (100 units/ml) with or without preincubation (20 min) with the indicated amounts of H7. After 4 h, the cells were harvested and CAT, luciferase, 
and fl-galactosidase activities were measured in the homogenates. CAT and luciferase activities were normalized to ,8-galactosidase activities as an 
internal standard for transfection efficiency. Values are given in percent of the relative activities measured in IL-6-treated cells in the absence of the 
inhibitor H7. All transfections were carried out in three independent experiments, standard errors never exceeded 10% of the given values. For details 
about he transfected constructs refer to section 2. APRE, acute-phase r sponse lement; pIRE, palindromic IL-6 and IFN-y response lement; LUC, 
fire-fly luciferase gene. 
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the IL-6RE of the ICAM-1 promoter. In gel retardation assays 
using a radiolabelled probe containing this element, he forma- 
tion of APRF-DNA complexes with nuclear extracts from 
IL-6-treated HepG2 cells preincubated with H7 was not re- 
duced when compared to extracts from cells treated with IL-6 
alone. Therefore, although IL-6-induced transactivation from 
IL-6REs is strongly inhibited by H7, binding of APRF to these 
elements i  not prevented by the inhibitor. 
3.5. IL-6-induced serine phosphorylation of APRF 
As shown previously, activated APRF is phosphorylated at 
both tyrosine and serine residues [12]. APRF tyrosine phospho- 
rylation was shown to be induced by IL-6 but it was still 
unknown whether the serine phosphorylation represents a con- 
stitutive modification of APRF or is induced by IL-6 as well. 
We next considered the possibility that APRF itself may be 
substrate of an IL-6-activated and H7-sensitive protein serine/ 
threonine kinase. Recently, we had demonstrated the existence 
of two APRF forms which slightly differ in mobility upon SDS- 
PAGE [15]. When APRF was analyzed by immunoprecipita- 
tion from HepG2 cell lysates and anti-phosphotyrosine m-
munoblotting it became apparent that the two tyrosine 
phosphorylated forms of APRF appear with different kinetics 
(Fig. 3). Whereas the 87-kDa form was found to be tyrosine 
phosphorylated as early as 2 min after IL-6 stimulation, the 
89-kDa form appeared only after 10 min. Since phosphoryla- 
tion of many proteins results in a reduced electrophoretic mo- 
bility upon SDS-PAGE, we examined whether an additional 
phosphorylation step converts the 87-kDa into the 89-kDa 
APRF form. In fact, when APRF immunoprecipitated from 
HepG2 cells treated with IL-6 for 20 rain was incubated with 
protein phosphatase 2A the predominant 89-kDa form of 
APRF in this sample was converted back to the 87-kDa form 
(Fig. 4A). This effect was specific for phosphatase 2A as protein 
phosphatase 1 was unable to dephosphorylate he 89-kDa 
APRF. Treatment with alkaline phosphatase eliminated both 
bands due to the removal of phosphotyrosine. We conclude 
that between 5 and 15 min after addition of IL-6 the tyrosine 
phosphorylated APRF undergoes a second phosphorylation, 
now at serine residues, causing its reduced electrophoretic mo- 
bility. A phosphorylation at threonine is not likely to occur 
since phosphoamino acid analysis of activated APRF did not 
yield any detectable phosphothreonine [12]. 
Interestingly, the IL-6-activated Stat 1~ protein does not 
undergo a comparable delayed mobility shift nor is its mobility 
affected by the treatment with the phosphatases 1 or 2A. There- 
fore, Stat 1~ is either not the target of such an IL-6-induced 
serine phosphorylation r such a phosphorylation if it occurs 
does not change the mobility of that protein. It is worth noting 
in this context hat Stat 1~ undergoes a mobility shift upon 
tyro sine phosphorylation [19] whereas APRF does not (unpub- 
lished observation). 
3.6. APRF serine phosphorylation is H7 sensitive 
To investigate whether the IL-6-induced APRF serine phos- 
phorylation could correlate to the H7-sensitive step required 
for IL-6 target gene induction we analyzed whether the addition 
of H7 is able to prevent it. We preincubated HepG2 cells with 
H7, stimulated the cells with IL-6, and then immunoprecipi- 
tated APRF and Star 1~ from the cell lysates. As shown in Fig. 
4B, H7 prevented the appearance of the 89-kDa form of APRF, 
indicating that the serine phosphorylation f APRF is inhibited 
by H7. This finding strongly suggests that the APRF serine 
phosphorylation represents the missing link between APRF 
activation by tyrosine phosphorylation at the plasma mem- 
brane and the induction of IL-6 target genes in the nucleus. 
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Fig. 2. Binding of APRF to the IL-6RE of the ICAM-1 promoter is
unaffected by H7 pretreatment. HepG2 cells were pretreated for 1 h 
with the indicated amounts of H7 and then incubated for further 15 rain 
without or with IL-6 (100 units/ml). The cells were harvested, and 
nuclear extracts (5/lg protein) analyzed ina gel-retardation assay using 
32p-labelled oligonucleotide comprising the palindromic IL-6/IFN-7 
response lement of the ICAM-1 promoter. After incubating nuclear 
extract with the probe, free DNA and DNA-protein complexes were 
separated by electrophoresis through anative polyacrylamide (4%) gel. 
The gel was fixed~ dried, and autoradiographed. 
4. Discussion 
Our recent work has demonstrated the existence of a remark- 
ably direct signalling pathway from the IL-6 plasma membrane 
receptor to the nucleus [12,14,15,22]. The transcription factor 
APRF rapidly associates with the IL-6 signal transducer gp130 
upon binding of ILo6 to the receptor, and is then tyrosine 
phosphorylated and translocated tothe nucleus [12]. These data 
suggested that APRF tyrosine phosphorylation is sufficient for 
the induction of IL-6 target genes. Accordingly, binding of 
APRF to the IL-6 response lement (APRE) of the rat ~2- 
macroglobulin gene was inhibited by the protein tyrosine ki- 
nase inhibitors genistein and tyrphostin but not by the serine/ 
threonine kinase inhibitors phingosine, H7, or W7 [15]. Fur- 
thermore, APRF DNA-binding activity could be demonstrated 
in cytosolic fractions of IL-6-treated cells indicating that the 
early events in IL-6 signal transduction yield an active APRF 
protein [14]. In fact, APRF activation could even be achieved 
by incubation of cell homogenates with IL-6 in the presence of 
ATP [15]. 
On the other hand, several groups have reported that the 
induction of immediate-early genes by IL-6, i.e. the genes for 
Jun-B, IRF-1, and TIS11, in hybridoma nd myeloma cells can 
be blocked by both tyrosine kinase inhibitors and H7 [5,6]. 
Therefore, the action of an H7-sensitive serine/threonine kinase 
is likely to be involved in the induction of these genes by IL-6. 
We had shown earlier that APRF is likely to play an important 
role in the induction of the Jun-B, IRF-1, and ICAM-1 imme- 
diate-early genes by IL-6 [22,23]. The promoters of all three 
promoters contain IL-6 response lements containing APRF 
binding sites which are able to confer IL-6 inducibility to con- 
trol promoters [22-24]. 
Therefore, despite the direct IL-6 signalling pathway which 
leads to a rapid accumulation of DNA-binding APRF in the 
nucleus, the induction of genes regulated by this transcription 
factor requires an additional, H7-sensitive step. Two alternative 
explanations seem possible: either that an additional transcrip- 
tion factor, which is regulated by serine/threonine phosphoryl- 
ation, is required, or that the APRF activation pathway itself 
harbours an as yet unrecognized step. The results presented 
here strongly favour the latter explanation. 
By transient ransfection of reporter gene constructs into 
hepatoma cells we could demonstrate that the activation of 
three immediate-early gene promoters by IL-6 is also sensitive 
to H7. Even more intriguing, when the IL-6 response lements 
of these promoters where fused to the thymidine kinase pro- 
moter the induction of these constructs was completely blocked 
by H7 as well. Since all three IL-6REs were shown by us to 
represent APRF binding sites this observation indicates the 
unknown H7-sensitive step to involve either APRF itself or a 
protein closely cooperating with APRF in the transactivation 
of target promoters. 
Our earlier and present results clearly indicate, however, that 
APRF tyrosine phosphorylation is sufficient to induce the 
DNA-binding capacity of the factor and that H7 does not 
interfere with this process, neither when binding to the ct2- 
macroglobulin APRE [15], the Jun-B IL-6RE [23], nor the 
ICAM-1 pIRE (this paper) is concerned. 
In this context, the observation was of interest hat after 
IL-6-stimulation of HepG2 cells two tyrosine phosphorylated 
APRF bands of apparent molecular sizes of 87 and 89 kDa 
were detected by immunoprecipitation and immunoblot analy- 
ses [15]. These two bands are observed with antibodies directed 
against he amino-terminal portion of Star 1 which cross-react 
with APRF (as used here) as well as with specific antibodies to 
APRF (unpublished ata). Furthermore, this effect is not re- 
stricted to hepatoma cells but also observed in all other cell 
types studied so far, i.e. in COS7 cells and in fibrosarcoma, 
hybridoma, and preadipocyte cell lines (unpublished ata). 
Since in contrast to the situation with Stat 1 [19] APRF tyrosine 
phosphorylation does not account for this mobility shift upon 
SDS gel-electrophoresis we considered the possibility that the 
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Fig. 3. Time-course of APRF tyrosine phosphorylation. HepG2 cells were treated for the times indicated with IL-6 (100 units/ml) and lyzed. The 
lysates were immunoprecipitated with an antiserum raised against the amino-terminal portion of Stat 1 [25] which cross-reacts with APRF [15]. The 
immunoprecipitates w re separated by SDS-PAGE (7% gel) and electroblotted to polyvinyldifluoride m mbrane. Tyrosine-phosphorylated proteins 
were detected on the blot using monoclonal ntibodies to phosphotyrosine and visualized by enhanced chemiluminescence. Th  band corresponding 
to Stat ls and the doublet of bands representing APRF are indicated. 
phenomenon reflects an additional post-translational modifica- 
tion of APRF. 
The time-course ofAPRF tyrosine phosphorylation (Fig. 3) 
demonstrates that the shift in APRF mobility occurs only about 
10 min after the tyrosine phosphorylation had started. There- 
fore, the two phenomena c n be discriminated between. Earlier 
results had shown that APRF from IL-6-treated HepG2 cells 
contains both phosphotyrosine and phosphoserine while 
phosphothreonine could not be detected [12]. Since phospho- 
rylation of many proteins causes considerable mobility shift in 
SDS gel-electrophoresis we considered the possibility that the 
APRF mobility shift may be due to an additional phosphoryl- 
ation. In fact, our results show that the shift can be reversed 
by treatment with protein phosphatase 2A and is prevented by 
pretreatment of the cells with H7. Hence the data clearly indi- 
cate that APRF undergoes an additional IL-6-induced phos- 
phorylation which, for the lack of the occurrence of 
phosphothreonine  the protein, presumably occurs at serine 
residues, and which is catalyzed by an H7-sensitive protein 
kinase. 
The coincidence of an H7-sensitive step required for the 
induction of IL-6 target genes and an H7-sensitive serine phos- 
phorylation of APRF suggests that both represent the same 
phenomenon, i.e. that the APRF serine phosphorylation is 
required for the factor to be active as a transactivating factor. 
It will be of great interest to prove this conclusion by identifying 
the serine residue(s) of APRF phosphorylated in response to 
IL-6 and by mutational nalysis of these residues. The data also 
clearly demonstrate that both gene induction and APRF activa- 
tion by IL-6 require the convergent action of at least two sig- 
nalling pathways. The Jak/Stat pathway accounts for tyrosine 
phosphorylation f APRF triggering the activation of its DNA- 
binding potential and nuclear translocation whereas the other 
pathway, which gives rise to APRF serine phosphorylation a d 
presumably is important in target gene induction, still needs to 
be identified. IL-6 activates the Ras/MAP kinase pathway in 
various target cells [31,32]. Furthermore, the p90 rsk serine/thre- 
onine kinase activated via this pathway is known to be H7 
sensitive [31]. However, our data using dominant-negative Ras
and Raf-1 kinase mutants do not support he involvement of
this pathway in IL-6 target gene induction. Therefore, the pro- 
tein kinase responsible for APRF serine phosphorylation as
well as the exact function of this modification will be important 
issues for future research. 
A B Statl (~ 
APRF 
-H7 +H7 - P1 P2A AP 
I I I . , I  
IL-6: 15' 7' 15' 
Fig. 4. Effects of phosphatases and H7 on the IL-6-induced APRF mobility shift. (A) HepG2 cells were stimulated with IL-6 (100 units/ml) without 
or with preincubation with H7 (50 ¢tM, 1 h) as indicated. The cells were lysed, immunoprecipitated, andimmunoblotted with anti-phosphotyrosine 
as described inthe legend to Fig. 3 and in section 2. (B) HepG2 cells were stimulated as indicated with IL-6 (100 units/ml), lyzed, and immunopre- 
cipitated as described above. The protein A-Sepharose-coupled immunoprecipitates w re incubated without or with purified protein phosphatase 
1 (P1), the catalytic subunit of protein phosphatase 2A (P2A), or intestine alkaline phosphatase (AP) for 30 min at 30°C. The immunoprecipitates 
were then separated by SDS-PAGE, blotted to polyvinyldifluoride m mbrane, and detected by anti-phosphotyrosine as described for Fig. 3. 
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